Quick Answer
CITIUS ONCOLOGY, INC. reported Diluted EPS of $0.34 per share (loss) for fiscal year 2025.
CITIUS ONCOLOGY, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.34 | -9.7% |
| 2024 | -$0.31 | -214.8% |
| 2023 | $0.27 | +242.1% |
| 2023 | -$0.19 | -258.3% |
| 2022 | $0.12 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$0.06 | +33.3% | +25.0% |
| June 30, 2025 | -$0.08 | -14.3% | +27.3% |
| March 31, 2025 | -$0.11 | -57.1% | -22.2% |
| December 31, 2024 | -$0.09 | -28.6% | -28.6% |
| June 30, 2024 | -$0.07 | -200.0% | +0.0% |
| March 31, 2024 | -$0.07 | -200.0% | +0.0% |
| December 31, 2023 | -$0.07 | — | -450.0% |
| September 30, 2023 | $0.02 | — | -71.4% |
- CITIUS ONCOLOGY, INC. showed a decrease of -9.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, CITIUS ONCOLOGY, INC.’s diluted eps has declined by 383.3% (from $0.12 per share to $0.34 per share (loss)).
- The most recent figure is from CITIUS ONCOLOGY, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: